文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

全球、区域和国家层面预防和管理注射吸毒人群中艾滋病毒和丙型肝炎的干预措施的覆盖情况:系统评价。

Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.

机构信息

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia.

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia.

出版信息

Lancet Glob Health. 2017 Dec;5(12):e1208-e1220. doi: 10.1016/S2214-109X(17)30373-X. Epub 2017 Oct 23.


DOI:10.1016/S2214-109X(17)30373-X
PMID:29074410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5683737/
Abstract

BACKGROUND: People who inject drugs (PWID) are a key population affected by the global HIV and hepatitis C virus (HCV) epidemics. HIV and HCV prevention interventions for PWID include needle and syringe programmes (NSP), opioid substitution therapy (OST), HIV counselling and testing, HIV antiretroviral therapy (ART), and condom distribution programmes. We aimed to produce country-level, regional, and global estimates of coverage of NSP, OST, HIV testing, ART, and condom programmes for PWID. METHODS: We completed searches of peer-reviewed (MEDLINE, Embase, and PsycINFO), internet, and grey literature databases, and disseminated data requests via social media and targeted emails to international experts. Programme and survey data on each of the named interventions were collected. Programme data were used to derive country-level estimates of the coverage of interventions in accordance with indicators defined by WHO, UNAIDS, and the UN Office on Drugs and Crime. Regional and global estimates of NSP, OST, and HIV testing coverage were also calculated. The protocol was registered on PROSPERO, number CRD42017056558. FINDINGS: In 2017, of 179 countries with evidence of injecting drug use, some level of NSP services were available in 93 countries, and there were 86 countries with evidence of OST implementation. Data to estimate NSP coverage were available for 57 countries, and for 60 countries to estimate OST coverage. Coverage varied widely between countries, but was most often low according to WHO indicators (<100 needle-syringes distributed per PWID per year; <20 OST recipients per PWID per year). Data on HIV testing were sparser than for NSP and OST, and very few data were available to estimate ART access among PWID living with HIV. Globally, we estimate that there are 33 (uncertainty interval [UI] 21-50) needle-syringes distributed via NSP per PWID annually, and 16 (10-24) OST recipients per 100 PWID. Less than 1% of PWID live in countries with high coverage of both NSP and OST (>200 needle-syringes distributed per PWID and >40 OST recipients per 100 PWID). INTERPRETATION: Coverage of HIV and HCV prevention interventions for PWID remains poor and is likely to be insufficient to effectively prevent HIV and HCV transmission. Scaling up of interventions for PWID remains a crucial priority for halting the HIV and HCV epidemics. FUNDING: Open Society Foundations, The Global Fund, WHO, UNAIDS, United Nations Office on Drugs and Crime, Australian National Drug and Alcohol Research Centre, University of New South Wales Sydney.

摘要

背景:注射吸毒者(PWID)是受全球 HIV 和丙型肝炎病毒(HCV)流行影响的关键人群。针对 PWID 的 HIV 和 HCV 预防干预措施包括针具和注射器方案(NSP)、阿片类药物替代疗法(OST)、HIV 咨询和检测、HIV 抗逆转录病毒治疗(ART)以及 condom 分发方案。我们旨在生成针对 PWID 的 NSP、OST、HIV 检测、ART 和 condom 方案的国家、区域和全球覆盖率估计数。

方法:我们完成了对同行评议(MEDLINE、Embase 和 PsycINFO)、互联网和灰色文献数据库的搜索,并通过社交媒体和针对国际专家的定向电子邮件分发了数据请求。收集了每个指定干预措施的方案和调查数据。根据世卫组织、联合国艾滋病规划署和联合国毒品和犯罪问题办公室定义的指标,使用方案数据推导出国家一级干预措施的覆盖范围。还计算了 NSP、OST 和 HIV 检测覆盖率的区域和全球估计数。该方案已在 PROSPERO 上注册,编号为 CRD42017056558。

结果:2017 年,在有注射吸毒证据的 179 个国家中,93 个国家提供了某种程度的 NSP 服务,86 个国家有 OST 实施的证据。有 57 个国家提供了估计 NSP 覆盖率的数据,有 60 个国家提供了估计 OST 覆盖率的数据。国家之间的覆盖率差异很大,但根据世卫组织的指标,大多数情况下覆盖率都很低(每年每 1 名 PWID 分发的针具数量不到 100 个;每年每 100 名 PWID 接受 OST 的人数不到 20 人)。HIV 检测数据比 NSP 和 OST 更为稀少,并且很少有数据可用于估计 HIV 阳性 PWID 获得 ART 的情况。全球范围内,我们估计每年有 33(不确定区间 [UI] 21-50)个 NSP 通过 PWID 分发的针具,以及 16(10-24)个 OST 接受者每 100 名 PWID。不到 1%的 PWID 生活在 NSP 和 OST 覆盖率高的国家(每 1 名 PWID 分发的针具数量超过 200 个,每 100 名 PWID 接受 OST 的人数超过 40 人)。

解释:针对 PWID 的 HIV 和 HCV 预防干预措施的覆盖率仍然很低,可能不足以有效预防 HIV 和 HCV 的传播。扩大针对 PWID 的干预措施仍然是遏制 HIV 和 HCV 流行的关键优先事项。

资助:开放社会基金会、全球基金、世卫组织、联合国艾滋病规划署、联合国毒品和犯罪问题办公室、澳大利亚国家药物和酒精研究中心、新南威尔士大学悉尼分校。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be6/5683737/31a143320a17/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be6/5683737/319c4ab8db56/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be6/5683737/09ece7467b4e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be6/5683737/1b6715dbc4c0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be6/5683737/31a143320a17/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be6/5683737/319c4ab8db56/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be6/5683737/09ece7467b4e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be6/5683737/1b6715dbc4c0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be6/5683737/31a143320a17/gr4.jpg

相似文献

[1]
Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.

Lancet Glob Health. 2017-10-23

[2]
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Cochrane Database Syst Rev. 2017-9-18

[3]
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.

Lancet Glob Health. 2017-10-23

[4]
Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review.

Lancet Glob Health. 2023-12

[5]
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis.

Lancet Gastroenterol Hepatol. 2025-4

[6]
Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews.

BMC Public Health. 2017-4-11

[7]
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.

Lancet. 2010-2-26

[8]
Effectiveness of pharmacy-based needle/syringe exchange programme for people who inject drugs: a systematic review and meta-analysis.

Addiction. 2017-2

[9]
Supervised dosing with a long-acting opioid medication in the management of opioid dependence.

Cochrane Database Syst Rev. 2017-4-27

[10]
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.

Cochrane Database Syst Rev. 2008-7-16

引用本文的文献

[1]
HIV Prevention Among People Who Inject Drugs (PWID): A Narrative Review.

Cureus. 2025-6-10

[2]
Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial.

JAMA. 2025-7-9

[3]
Understanding drug-related harms as risk-amplifying loops among people who inject drugs in Sweden.

Harm Reduct J. 2025-7-4

[4]
Assessing Spillover Effects of Medications for Opioid Use Disorder on HIV Risk Behaviors among a Network of People Who Inject Drugs.

Stats (Basel). 2024-6

[5]
Reaching High: Translating Emergent Practices of Street-Level Drug Users to Institute Harm Reduction in Durban-Implications for Urban Governance.

Urban Forum (Johannesbg). 2022

[6]
Recruiting opioid treatment program administrators for a national survey: Outcomes and lessons learned.

Int J Drug Policy. 2025-5

[7]
Prevalence of hepatitis B and C, and their linkage to care among drug abusers attending psychiatric hospital in Hiroshima, Japan.

GHM Open. 2024-7-31

[8]
Proinflammatory Biomarkers and Clinical Factors Associated with Long-Term Mortality in People with HIV.

Viruses. 2025-2-11

[9]
Supervised Injecting Room Cohort Study (SIRX): study protocol.

BMJ Open. 2025-2-11

[10]
Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023).

Open Forum Infect Dis. 2024-12-17

本文引用的文献

[1]
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.

Lancet Glob Health. 2017-10-23

[2]
Global AIDS Reporting-2001 to 2015: Lessons for Monitoring the Sustainable Development Goals.

AIDS Behav. 2017-7

[3]
HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary-An expanding public health burden.

Int J Drug Policy. 2017-3

[4]
HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015.

N Engl J Med. 2016-7-21

[5]
Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement.

Lancet. 2016-6-28

[6]
High Prevalence and Incidence of HIV and HCV Among New Injecting Drug Users With a Large Proportion of Migrants--Is Prevention Failing?

Subst Use Misuse. 2016-1-28

[7]
The Global Fund to Fight AIDS, Tuberculosis and Malaria's investments in harm reduction through the rounds-based funding model (2002-2014).

Int J Drug Policy. 2016-1

[8]
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention.

Curr Opin HIV AIDS. 2015-9

[9]
Errors in reported degrees and respondent driven sampling: implications for bias.

Drug Alcohol Depend. 2014-9-1

[10]
Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study.

PLoS One. 2013-11-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索